CollPlant Biotechnologies Ltd Ordinary Shares (CLGN) — Analysis Summary
CollPlant Biotechnologies Ltd Ordinary Shares (CLGN) has a market cap of $5.48M with year-over-year revenue growth of +360.4%. Net margin stands at -484.6%. The stock trades at a P/E ratio of -0.5.
Key Takeaways
- Revenue changed +360.4% year-over-year
- Net margin of -484.6%
- P/E ratio of -0.5
Compared with its sector, CLGN posted revenue growth of +360.4% and trades at a P/E of -0.5.
CollPlant Biotechnologies Ltd Ordinary Shares (CLGN)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -484.3% — severe operating losses
Net margin at -484.6% — losses exceed revenue (possible one-time charges)
The latest filing shows negative free cash flow.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
Employees
39
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.